Overview
SABS market data
Price History
SABS price chart · 1M
- O
- 3.88
- H
- 3.92
- L
- 3.85
- C
- 3.92
- Vol
- 23,576.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $3.88
- Previous Close
- $3.87
- Day High
- $3.92
- Day Low
- $3.85
- 52 Week High
- $4.58
- 52 Week Low
- $3.29
- 7 Day Return
- +6.23%
- 30 Day Return
- +13.29%
- 90 Day Return
- +9.04%
- 1 Year Return
- +12.00%
- Daily Notional Volume
- $92.4K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 26.12 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.22 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.60 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -1,795.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.85 – $5.15 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $346.7M · P/B 1.18 · P/S 262.06.
Company News
SAB Biotherapeutics Q2 2026, Cash Balance Of $208.0M, Providing Runway Through 2028Benzinga · Aug 6, 2026, 11:36 AM
SAB Biotherapeutics Receives Breakthrough T1D Grant To Advance SAB-142 Study In Newly Diagnosed Type 1 DiabetesBenzinga · Jul 7, 2026, 12:20 PM
Barclays Initiates Coverage On SAB Biotherapeutics with Overweight Rating, Announces Price Target of $13Benzinga · Jun 24, 2026, 6:55 PM
Chardan Capital Maintains Buy on SAB Biotherapeutics, Raises Price Target to $16Benzinga · Jun 17, 2026, 12:40 PM
Paychex To Rally More Than 39%? Here Are 10 Top Analyst Forecasts For MondayBenzinga · Jun 15, 2026, 2:00 PM
Leerink Partners Maintains Outperform on SAB Biotherapeutics, Raises Price Target to $12Benzinga · Jun 15, 2026, 1:05 PM